Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs

Journal of the National Cancer Institute

Volumn 98, Issue 16, 2006, Pages 1118-1128

  Hicks, Kevin O ^a   Pruijn, Frederik B ^a   Secomb, Timothy W ^b   Hay, Michael P ^a   Hsu, Richard ^b   Brown, J Martin ^c   Denny, William A ^a   Dewhirst, Mark W ^d   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TIRAPAZAMINE; TIRAPAZAMINE DERIVATIVE; UNCLASSIFIED DRUG; RADIOSENSITIZING AGENT; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL STRAIN HT29; CELL SUSPENSION; CLONOGENIC ASSAY; COLON CANCER; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOTOXICITY; DIFFUSION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG TARGETING; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; TISSUE CULTURE; TUMOR CELL DESTRUCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ACTIVE TRANSPORT; ANALYSIS OF VARIANCE; ANIMAL; ANOXIA; CELL CULTURE; COLON TUMOR; COMPARATIVE STUDY; DISEASE MODEL; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; REPRODUCIBILITY; VASCULARIZATION; XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; MICE; RADIATION-SENSITIZING AGENTS; REPRODUCIBILITY OF RESULTS; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 33747443851     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj306     Document Type: Article

References (40)

1. Minchinton AI, Tannock IF. Drug penetration in solid tumors. Nat Rev Cancer 2006;6:583-92.
2. Hicks KO, Ohms SJ, van Zijl PL, Denny WA, Hunter PJ, Wilson WR. An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer 1997;76:894-903.
3. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
4. Dewhirst MW, Richardson R, Cardenas-Navia I, Cao Y. The relationship between the tumor physiologic microenvironment and angiogenesis. Hematol Oncol Clin North Am 2004;18:973-90.
5. Wijffels KI, Kaanders JH, Rijken PF, Bussink J, van den Hoogen FJ, Marres HA, et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer 2000;83:674-83.
6. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46:149-68.
7. Jain RK. The next frontier of molecular medicine: Delivery of therapeutics. Nat Med 1998;4:655-7.
8. Tannock IF. Conventional cancer theraphy: Promise broken or promise delayed? Lancet 1998;351(Suppl 2):9-16.
9. Hicks KO, Fleming Y, siim BG, Koch CJ, Wilson WR. Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys 1998;42:641-9.
10. Hicks KO, Pruijn FB, Baguley BC, Wilson WR. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(dimethylamino)ethyl] acridine-4-carboxamide (DACA): Diffusion and metabolism in multicellular layers of tumor cells. J Pharmacol Exp Ther 2001;297:1088-98.
11. Kyle AH, Minchinton AI. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 1999;43:213-20.
12. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 2005;23:79-87.
13. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986;12:1239-42.
14. Daniels JS, Gates KS. DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233): Evidence for involvement of hydroxyl radical. J Am Chem Soc 1996;118:3380-5.
15. Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J Am Chem Soc 2003;125:748-56.
16. Baker MA, Zeman EM, Hirst VK, Brown JM. Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity. Cancer Res 1988;48:5947-52.
17. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
18. Durand RE, Olive PL. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig 1997;5:213-9.
19. Durand RE, Olive PL. Evaluation of bioreductive drugs in multicell spheroids. Int J Radiat Oncol Biol Phys 1992;22:689-92.
20. Pruijn FB, Sturman JR, Liyanage HDS, Hicks KO, Hay MP, Wilson WR. Extravascular transport of drugs in tumor tissue: Effect of lipophilicity on diffusion of tirapazamine analogs in multicellular layer cultures. J Med Chem 2005;48:1079-87.
21. Hay MP, Pruijn FB, Gamage SA, Liyanage HD, Kovacs MS, Patterson AV, et al. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: Potent analogues of the hypoxia-selective cytotoxin tirapazamine. J Med Chem 2004;47:475-88.
22. Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 2003;63:5970-7.
23. Secomb TW, Hsu R, Braun RD, Ross JR, Gross JF, Dewhirst MW. Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv Exp Med Biol 1998;454:629-34.
24. Hall EJ. Radiobiology for the radiologist. 5th ed. Philadelphia (PA): J.B. Lippincott Company; 2000.
25. Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, et al. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem 2003;46:169-82.
26. Shinde SS, Anderson RF, Hay MP, Gamage SA, Denny WA. Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides. J Am Chem Soc 2004;126:7865-74.
27. Hay MP, Denny WA. New and versatile synthesis of 3-alkyl- and 3-aryl-1,2,4-benzotriazine 1,4-dioxides: Preparation of the bioreductive cytotoxins SR4895 and SR4941. Tetrahedron Lett 2002;43:9569-71.
28. Delahoussaye YM, Hay MP, Pruijn FB, Denny WA, Brown JM. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem Pharmacol 2003;65:1807-15.
29. Siim BG, Hicks KO, Pullen SM, van Zijl PL, Denny WA, Wilson WR. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism. Biochem Pharmacol 2000;60:969-78.
30. Hicks KO, Siim BG, Pruijn FB, Wilson WR. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: Implications for extravascular transport and activity in tumors. Radiat Res 2004;161:656-66.
31. Wilson WR, Pullen SM, Hogg A, Hobbs SM, Pruijn FB, Hicks KO. In vitro and in vivo models for evaluation of GDEPT: Quantifying bystander killing in cell cultures and tumors. In: Springer CJ, editor. Suicide gene therapy: Methods and reviews. Totowa (NJ): Humana Press; 2003. p. 403-32.
32. Dewhirst MW, Secomb TW, Ong ET, Hsu R, Gross JF. Determination of local oxygen consumption rates in tumors. Cancer Res 1994;54:3333-6.
33. Secomb TW, Hsu R, Park EY, Dewhirst MW. Green's function methods for analysis of oxygen delivery to tissue by microvascular networks. Ann Biomed Eng 2004;32:1519-29.
34. Kavanagh BD, Secomb TW, Hsu R, Lin PS, Venitz J, Dewhirst MW. A theoretical model for the effects of reduced hemoglobin-oxygen affinity on tumor oxygenation. Int J Radiat Oncol Biol Phys 2002;53:172-9.
35. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984;10:695-712.
36. Flicks KO, Patel K, Pruijn FB, Hay MP, Wilson WR. Effect of cell type and drug lipophilicity on the extravascular transport of small molecule anticancer drugs: Tirapazamine analogs. Proc Am Assoc Cancer Res 2005;46:969.
37. Koch CJ. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 1993;53:3992-7.
38. Bussink J, Kaanders JH, Rijken PF, Peters JP, Hodgkiss RJ, Marres HA, et al. Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: Effects of carbogen and nicotinamide. Radiother Oncol 1999;50:173-84.
39. Bussink J, Kaanders JH, Strik AM, Vojnovic B, Der Kogel AJ. Optical sensor-based oxygen tension measurements correspond with hypoxia marker binding in three human tumor xenograft lines. Radiat Res 2000;154:547-55.
40. Olive PL, Banath JP, Sinnott LT. Phosphorylated histone H2AX in spheroids, tumors, and tissues of mice exposed to etoposide and 3-amino-1,2,4-benzotriazine-1,3-dioxide. Cancer Res 2004;64:5363-9.